期刊文献+

成人哮喘慢性持续期肺功能与白三烯水平相关性研究 被引量:4

Association between pulmonary function and leukotriene ir adult chronic persistent asthmatic patients
下载PDF
导出
摘要 目的:观察机体白三烯水平与成人支气管哮喘慢性持续期肺功能指标第1秒用力呼气容积(forced expiratory volume in one second,FEV1)/用力肺活量(forced vital capacity,FVC)比值及FEV1值的相关性,探讨白三烯水平对慢性持续期哮喘患者肺功能的影响。方法:募集成人慢性持续期哮喘患者96例,所有患者均按常规吸入福莫特罗/布地奈德进行基础治疗。治疗前及治疗后8周用ELISA检测尿白三烯E4(leukotriene E4,LTE4)浓度,用肺功能仪检测患者FVC值及FEV1值。同时募集健康对照者40例,检测尿LTE4水平。比较健康对照者与不同病情严重程度哮喘患者尿LTE4水平的差异,以及FEV1/FVC及FEV1值与尿LTE4水平的相关关系。结果:1)轻度持续、中度持续及重度持续期哮喘患者尿LTE4浓度均高于健康对照组(P<0.05),且随着病情严重度增加尿LTE4浓度也升高。2)初始治疗前中度持续期患者FEV1/FVC及FEV1值与尿LTE4浓度均呈负相关(P<0.05)。结论:中度持续的哮喘患者肺功能与体内白三烯水平关系更为密切,中、重度持续的哮喘患者初始治疗时加用白三烯受体拮抗剂可能会更快改善肺功能。 Objective: To investigate the effect of leukotriene levels on the pulmonary function of patients with chronic persistent asthma, and to observe the correlation between concentration of leukotriene E4 (LTE4) in urine and the patients forced expiratory volume in the ifrst second (FEV1)/forced vital capacity (FVC) and FEV1 value. Methods: Ninety-six patients of asthma were studied and classified into three groups based on the severity of expiratory airlfow limitation: 1) mild persistent asthmatic group (FEV1 〉80% predicted) included 40 patients; 2) moderate persistent asthmatic group (FEV1 of 60% to 80% predicted) included 48 patients; and 3) severe persistent asthmatic group (FEV1 〈60% predicted) included 8 patients. All patients were used budesonide and 〈br〉 formoterol fumarate powder for inhalation. Before treatment and atfer treatment for 8 weeks, the concentration of urinary LTE4 were detected by ELISA, FEV1/FVC and FEV1 measured by pulmonary function instrument. At the same time, 40 cases of healthy controls were collected to detect the urinary LTE4.Results: 1) urinary LTE4 concentrations in mild, moderate and severe persistent patients were higher than those in healthy control group (P〈0.05), and with the severity of the disease, the urinary LTE4 concentration was increased; 2) FEV1/FVC and FEV1 values were negatively correlated (P〈0.05) in patients with moderate persistent asthma before budesonide and formoterol fumarate powder for inhalation treatment.Conclusion:The correlation between pulmonary function and leukotriene levels in moderate persistent asthmatic patients was more closely, moderate persistent and severe persistent asthmatic patients would beneift from administrated leukotriene receptor antagonist agents.
出处 《临床与病理杂志》 CAS 2015年第8期1487-1492,共6页 Journal of Clinical and Pathological Research
基金 国家自然科学基金项目资助(81460250) 广西自然科学基金项目资助(2012GXNSFAA053128)~~
关键词 支气管哮喘 白三烯 FEV1 FVC FEV1/FVC asthma leukotriene FEVI FVC FEV1/FVC
  • 相关文献

参考文献9

  • 1Elias JA, Lee CG, Zheng T, et al. New insights into the pathogenesis of asthma[J].J Clin Invest, 2003,111(3): 291-297.
  • 2Rajanandh MG, Nageswari AD, llango K. Pulmonary function assessment in mild to moderate persistent asthma patients receiving montelukast, doxofylline, and tiotropium with budesonide: a randomized controlled study[J]. Clin 21~er, 2014, 36(4): 526-533.
  • 3支气管哮喘防治指南(支气管哮喘的定义、诊断、治疗和管理方案)[J].中华结核和呼吸杂志,2008,31(3):177-185. 被引量:2517
  • 4Singh RK, Tandon R, Dastidar SG, et al. A review on leukotrienes and their receptors with reference to asthma[J]. J Asthma, 2013, 50(9): 922-931.
  • 5Capriles Hulett A, Yibirin MG, Garcia A, et al. Montelukast for the high impact of asthma exacerbations in Venezuela: a practical and valid approach for Latin America?[J]. World Allergy Organ J, 2014, 7(1): 20.
  • 6Keast SL, Thompson Dj Farmer K, et al. Impact of a prior authorization policy for montelukast on clinical outcomes for asthma and allergic rhinitis among children and adolescents in a state Medicaid program[J]. J Manag Care Spec Pharm, 2014, 20(6): 612-621.
  • 7Rajanandh MG, Nageswari AD, Ilango K. Pulmonary function assessment in mild to moderate persistent asthma patients receiving montelukast, doxofylline, and tiotropium with budesonide: a randomized controlled study[J]. Clin Ther, 2014, 36(4): 526-533.
  • 8Christie PE, Tagari P, Ford-Hutchinson AW, et al. Increased urinary LTE4 excretion following inhalation of LTC4 and LTE4 in asthmatic subjects[J]. Eur Respir J, 1994, 7(5): 907-913.
  • 9夏阳,白冲,徐永健.慢性阻塞性肺疾病患者尿白三烯E4的变化[J].临床肺科杂志,2011,16(7):987-988. 被引量:6

二级参考文献10

  • 1慢性阻塞性肺疾病诊治指南(2007年修订版)[J].中华结核和呼吸杂志,2007,30(1):8-17. 被引量:8229
  • 2Smith CM,Hawksworth RJ,Thien FC.Urinary leukotriene E4 in bronchial asthma[J].Eur Respir J,1992,5(6):693-699.
  • 3Shindo K,Hiral Y,Fukumura M.Plasma levels of leukotriene E4 during clinical course of chronic obstructive pulmonary disease[J].ProstaglandinsLeukot Essent Fatty Acids,1997,56(3):213.
  • 4Cazzola M,Centanni S,Boveri B.Comparison of the bronchodilating effect of salmeterol and zafrlukast in combination with that of their use as single treatment in asthma and chronic obstructive pulmonary disease[J].Respiration,2001,68:452.
  • 5Lewis RA,Austen KF,Spberman RJ.Leukotriences and other product of the 5-lipoxygenase pathway.Biochemistry and relation to pathobiology in human disease[J].N Engl J Med,1990,323:645.
  • 6Samitas K,Chorianopoulos D,Vittorakis S.Exhaled cysteinyl-leukotrienes and 8-isoprostane in patients with asthma and their relation to clinical severity[J].Respir Med,2009,103(5):750-756.
  • 7Kostikas K,Gaga M,Papatheodorou G.Leukotriene B4 in exhaled breath condensate and sputum supernatant in patients with COPD and asthma[J].Chest,2005,127(5):1553.
  • 8Bleecker ER,Similarlities and differences in asthma:the Dutch hypothesis[J].Chest,2004,126(suppl):93S.
  • 9Mita H,Turikisawa N,Yamada T,Taniguchi M.Quantification of leukotriene B4 glucuronide in human urine[J].Prostaglandins Other Lipid Mediators,2007,83(1):42-49.
  • 10俞小卫,韦国桢,林亚媛,吴秀梅,周仪顺.慢性阻塞性肺疾病患者血清白三烯和α_1-抗胰蛋白酶的变化[J].南京医科大学学报(自然科学版),2004,24(2):182-184. 被引量:24

共引文献2521

同被引文献36

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部